| Test |
In Range |
Out Of Range |
Units |
Reference |
| CBC with Differential/Platelet |
|
|
|
|
| WBC |
5.9 |
|
x10E3/uL |
3.4 - 10.8 |
| RBC |
|
L 3.99 |
x10E6/uL |
4.14 - 5.80 |
| Hemoglobin |
13.2 |
|
g/dL |
13.0 - 17.7 |
| Hematocrit |
39.4 |
|
% |
37.5 - 51.0 |
| MCV |
|
99 H |
fL |
79 - 97 |
| MCH |
|
33.1 H |
pg |
26.6 - 33.0 |
| |
| MCHC |
33.5 |
|
g/dL |
31.5 - 35.7 |
| RDW |
12.1 |
|
% |
11.6 - 15.4 |
| Platelets |
253 |
|
x10E3/uL |
150 - 450 |
| Neutrophils |
61 |
|
% |
|
| Lymphs |
22 |
|
% |
|
| |
| Monocytes |
11 |
|
% |
|
| EOS |
4 |
|
% |
|
| Basos |
1 |
|
% |
|
| Neutrophils (Absolute) |
3.7 |
|
x10E3/uL |
1.4 - 7.0 |
| Lymphs (Absolute) |
1.3 |
|
x10E3/uL |
0.7 - 3.1 |
| |
| Monocytes (Absolute) |
0.6 |
|
x10E3/uL |
0.1 - 0.9 |
| EOS (Absolute) |
0.2 |
|
x10E3/uL |
0.0 - 0.4 |
| Baso (Absolute) |
0.0 |
|
x10E3/uL |
0.0 - 0.2 |
| Immature Granulocytes |
1 |
|
% |
|
| Immature Grans (Abs) |
0.0 |
|
x10E3/uL |
0.0 - 0.1 |
| |
| SARS-CoV-2 Semi-Quant Spike Ab |
See Dilution |
|
U/mL |
Neg < 0.8 |
| SARS-CoV-2 Spike Ab Dilution |
15510 |
|
U/mL |
Neg < 0.8 |
| SARS-CoV-2 Spike Ab Interp |
Positive |
|
|
|
| |
Antibodies against the SARS-CoV-2 spike protein recepteor binding domain (RBD) were detected. It is yet undetermined what level of antibody to SARS-CoV-2 spike protein correlates to immunity against developing symptomatic SARS-CoV-2 disease. Studies are underway to measure the quantitative levels of specific SARS-CoV-2 antibodies following vaccination. Such studies will provide valuable insights into the correlation between protection from vaccination and antibody levels.
Roche Elecsys Anti-SARS-CoV-2 S |
| |
| Ferritin |
81 |
|
ng/mL |
30 - 400 |